Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th
Viridian Therapeutics (NASDAQ: VRDN) will participate in the Guggenheim 4th Annual Neuro/Immunology Conference on November 15, 2022. The company will host a fireside chat at 1:35 p.m. ET. Investors can access the live webcast and subsequent replay through the company's Investors section. Viridian is focused on developing treatments for serious diseases, including thyroid eye disease.
- None.
- None.
WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that management will participate in the Guggenheim 4th Annual Neuro/Immunology Conference on Tuesday, November 15, 2022.
Guggenheim 4th Annual Neuro/Immunology Conference
| Format: | Fireside Chat |
| Date: | November 15, 2022 |
| Time: | 1:35 p.m. ET |
| Webcast link: | Registration link |
The live webcast and a replay of the fireside chats can also be accessed under “Events” in the Investors section of the Viridian Therapeutics website.
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies. Viridian’s most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). VRDN-002 is a distinct anti-IGF-1R antibody and incorporates half-life extension technology. VRDN-003 is an extended half-life version of VRDN-001. Both VRDN-002 and VRDN-003 are designed for administration as convenient, low-volume, subcutaneous injections. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Viridian is based in Waltham, Massachusetts.
Investor and Media Contact:
John Jordan
Viridian Therapeutics
Vice President, Investor Relations
& Corporate Communications
617-272-4691
IR@viridiantherapeutics.com
FAQ
When will Viridian Therapeutics participate in the Guggenheim Annual Neuro/Immunology Conference?
What time is Viridian's fireside chat at the conference?
How can I access the webcast for Viridian's fireside chat?
What is the focus of Viridian Therapeutics' research?
